Circio Holding ASA: Registration of share capital increase following warrant exercise and private placement
Oslo, 6 January 2025: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company“) on 19 December 2024, regarding the final results of the warrant exercise for the 13,864,852 warrants (the “Warrants“), issued in connection with the rights issue, where 12,921,088 Warrants were exercised, resulting in an aggregate subscription of 12,921,088 new shares in the Company (“New Shares“), and the stock exchange announcement published on 18 December 2024 regarding completion of a private placement of 4,903,925 new shares (the “Private Placement“).
The share capital increases related to the warrants exercise and the Private Placement have been registered with the Norwegian Register of Business Enterprises today, 6 January 2025. The Company’s new share capital is NOK 42,090,397.20 divided into 70,150,662 shares, each with a nominal value of NOK 0.60.
The new shares related to the warrant exercise and the Private Placement will, following the registration of the share capital increases, be issued and delivered as soon as practically possible.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.